Hopp til hovedinnhold

Neglesopp

Sist oppdatert: Sist revidert:
Sist revidert av:


Definisjon:
Soppinfeksjon i neglene, som regel forårsaket av T. rubrum.
Forekomst:
Forekommer hos ca. 10%, og forekomsten øker med årene
Symptomer:
Klinisk diagnose kan være vanskelig. Neglesopp utgjør 50% av alle negl-forandringene på tær
Funn:
Neglesopp gir som regel matte, skjøre negler med gul misfarging, hyperkeratose, onycholyse. Etter hvert blir neglen fortykket og deformert
Diagnostikk:
Mikroskopering av avskrap i KOH-løsning, dyrkning eller PCR kan bekrefte diagnosen
Behandling:
Som oftest er tåneglforandringer bare av kosmetisk karakter, og behandling er ikke nødvendig. Ved sterkt behandlingsønske/subjektivt besvær er både lokal og systemisk behandling er tilgjengelig, systemisk behandling er mest effektivt, men forbundet med potensielle bivirkninger. Sjansen for residiv er stor.
  1. Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician 2013; 88: 762-70. American Family Physician  
  2. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003;149(suppl 65):1-4.
  3. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.
  4. Hartman TC, van Rijswijk E. Fungal nail infection. BMJ 2008; 337: a429. PubMed  
  5. Austad J, Gjersvik PJ. Behandling av neglesopp. Tidsskr Nor Lægeforen 2001; 121: 606-7. Tidsskrift for Den norske legeforening  
  6. Tosti A. Onychomycosis clinical presentation. Medscape, last updated Jul 13, 2017. emedicine.medscape.com  
  7. Garcia-Doval I, Cabo F, Monteagudo B, et al. Clinical diagnosis of onychomycosis is possible in some patients: cross-sectional diagnostic study and development of a diagnostic rule. Br J Dermatol 2010; 163: 743-51. PubMed  
  8. Walberg M, Mørk C, Sandven P, et al. 18S rDNA polymerase chain reaction and sequencing in onychomycosis diagnostics. Acta Derm Venereol 2006; 86: 223-6. PubMed  
  9. Alberhasky RC. Laboratory diagnosis of onychomycosis. Clin Podiatr Med Surg. 2004;21(4):565–578.
  10. Statens legemiddelverk. Terapianbefaling: Behandling av dermatomykoser. Nytt om legemidler 2005; 28 (2): 28-33.
  11. Barr KL. Dermatophyte infections. BestPractice, last updated Aug 01, 2013 .
  12. Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. Dermatol Online J 2013. pmid:24050286 PubMed  
  13. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-44. PubMed  
  14. Kreijkamp-Kaspers S, Hawke KL, van Driel ML. Oral medications to treat toenail fungal infections. JAMA Clinicla Evidence Synopsis. JAMA 2018; 319: 397-8. pmid:29362778 PubMed  
  15. de Sá DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 ;15(1):17-36. doi: 10.1007/s40257-013-0056-2.
  16. Piraccini BM, Sisti A, Tosti A. Long-term follow up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agentS. J Am Acad Dermatol 2010; 62: 411-4. PubMed  
  17. Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol 2013; 30: 316-22. pmid:23278851 PubMed  
  18. Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 773-81. pmid:PMID: 19453778 PubMed  
  19. Iorizzo M, Hartmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail laquer inthe treatment of mild-to-moderate onychomycosis: A randomized, double.blind amorolfine controlled study using a blinded evaluator. Skin Appedndage Disord 2015; 1: 134-40. doi:10.1159/000441569 DOI  
  20. Paul C, Coustou D, Lahfa M, et al. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.. Dermatology 2013; 227 (2): 157-64. pmid:24051622 PubMed  
  21. Eisman S, Sinclair R. Fungal nail infection: diagnosis and management. BMJ. 2014 Mar 24;348:g1800. doi: 10.1136/bmj.g1800. DOI  
  22. Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother 2015; 16: 227-36. pmid:25522979 PubMed  
  23. Barot BS, Parejiya PB, Patel HK, et al. Drug delivery to the nail: therapeutic options and challenges for onychomycosis. Crit Rev Ther Drug Carrier Syst 2014; 31: 459-94. pmid:Crit Rev Ther Drug Carrier Syst
  24. Ma W, Si C, Kasyanju Carrero LM, et al. Laser treatment for onychomycosis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(48):e17948. PubMed  
  25. Goldstein AO, Bhatia N. Onychomycosis: Management. UpToDate, last updated Nov 20, 2020. UpToDate  
  26. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm Venereol 2010; 90: 216. pmid:20169321 PubMed  
  • Morten Dalaker, avtalespesialist i hudsykdommer, Trondheim Hudlegesenter, Carl Johans gt 3, 7010 Trondheim
  • Tor Andre Johannessen, lege og redaktør NEL

Tidligere fagmedarbeidere

  • Sylvi Torvund, spesialist i allmennmedisin, Nardosletta legesenter, Trondheim